(British Approved Name Modified, US Adopted Name, rINNM)
INNs in main languages (French, Latin, Russian, and Spanish):
Pharmacopoeias. In Japan.
Adverse Effects and Precautions
Chlorphenesin carbamate produces drowsiness and dizziness. There may also be nausea, headache, weakness, confusion, agitation, and insomnia. Hypersensitivity reactions have been reported. There are rare reports of blood disorders. It should be used with caution in patients with hepatic impairment. Patients affected by drowsiness should not drive or operate machinery.
The CNS effects of chlorphenesin carbamate may be potentiated by alcohol or other CNS depressants.
Chlorphenesin carbamate is readily and completely absorbed from the gastrointestinal tract and partly metabolised in the liver. It is excreted in the urine, mainly as the glucuronide metabolite.
Uses and Administration
Chlorphenesin carbamate is a centrally acting skeletal muscle relaxant related to mephenesin. Its mode of action may be related to general depressant effects on the CNS. It is used as an adjunct in the symptomatic treatment of painful muscle spasm associated with musculoskeletal conditions. The usual initial oral dose is 250 mg three times daily, adjusted according to response. It has been recommended that chlorphenesin carbamate should not be given for longer than 8 weeks. Chlorphenesin base is used as an antifungal.
United States of America (US and USA): Maolate.